3.9 Article

Signal transduction for formation/release of interleukin-8 caused by a PAR2-activating peptide in human lung epithelial cells

Journal

REGULATORY PEPTIDES
Volume 145, Issue 1-3, Pages 42-48

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.regpep.2007.08.002

Keywords

proteinase-activated receptor-2; MAP kinase; ERK; JNK; EGF receptor; tyrosine kinase

Ask authors/readers for more resources

Proteinase-activated receptor-2 (PAR2) plays a dual role in the respiratory system, being pro- and anti-inflammatory. In human lung epithelial cells (A549), PAR2 activation causes release of interleukin-8 (IL-8) in addition to prostaglandin E-2 (PGE(2)). In the present study, we thus investigated PAR2-triggered signal transduction pathways causing IL-8 formation in A549 cells. SLIGRL-NH2, a PAR2-activating peptide, but not LSIGRL-NH2,, a scrambled peptide, elicited release of IL-8 from A549 cells for 18 h, as measured by the ELISA method, an effect being suppressed by inhibitors of MEK, JNK, EGF receptor-tyrosine kinase (EGFR-TK), Src, pan-tyrosine kinases and protein kinase C, but not p38 MAP kinase or cyclooxygenase. SLIGRL-NH2, also up-regulated IL-8 at protein and mRNA levels, as determined by Western blotting and RTPCR, respectively. The PAR2-triggered up-regulation of IL-8 protein and mRNA was blocked by an inhibitor of MEK, but not clearly by inhibitors of JNK and EGFR-TK. SLIGRL-NH2 actually phosphorylated JNK as well as ERK, the JNK activation being resistant to inhibitors of Src, pan-tyrosine kinases, protein kinase C and EGFR-TK. Our data suggest that PAR2-triggerd IL-8 formation involves transcriptional upregulation of IL-8 via the MEK-ERK pathway, while the JNK and EGF receptor pathways might rather contribute to a post-transcriptional process for the release of IL-8. (c) 2007 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.9
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Neurosciences

Role of Thrombin in Soluble Thrombomodulin-Induced Suppression of Peripheral HMGB1-Mediated Allodynia in Mice

Ryuichi Tsujita, Maho Tsubota, Yusuke Hayashi, Haruka Saeki, Fumiko Sekiguchi, Atsufumi Kawabata

JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2018)

Article Biochemistry & Molecular Biology

Human soluble thrombomodulin-induced blockade of peripheral HMGB1-dependent allodynia in mice requires both the lectin-like and EGF-like domains

Yusuke Hayashi, Ryuichi Tsujita, Maho Tsubota, Haruka Saeki, Fumiko Sekiguchi, Goichi Honda, Atsufumi Kawabata

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)

Article Neurosciences

Paclitaxel-induced HMGB1 release from macrophages and its implication for peripheral neuropathy in mice: Evidence for a neuroimmune crosstalk

Fumiko Sekiguchi, Risa Domoto, Kana Nakashima, Daichi Yamasoba, Hiroki Yamanishi, Maho Tsubota, Hidenori Wake, Masahiro Nishibori, Atsufumi Kawabata

NEUROPHARMACOLOGY (2018)

Article Health Care Sciences & Services

The C-Reactive Protein/Albumin Ratio Is Useful for Predicting Short-Term Survival in Cancer and Noncancer Patients

Tomoyoshi Miyamoto, Masanori Fujitani, Hiroki Fukuyama, Shigekatsu Hatanaka, Yuichi Koizumi, Atsufumi Kawabata

JOURNAL OF PALLIATIVE MEDICINE (2019)

Article Pharmacology & Pharmacy

NNC 55-0396, a T-type calcium channel blocker, protects against the brain injury induced by middle cerebral artery occlusion and reperfusion in mice

Sachi Matsuda, Hiroyuki Nishikawa, Anna Fukatsu, Yuko Kurokawa, Maho Tsubota, Fumiko Sekiguchi, Shogo Tokuyama, Atsufumi Kawabata

JOURNAL OF PHARMACOLOGICAL SCIENCES (2019)

Article Pharmacology & Pharmacy

Critical role of Cav3.2 T-type calcium channels in the peripheral neuropathy induced by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice

Shiori Tomita, Fumiko Sekiguchi, Tomoyo Deguchi, Takaya Miyazaki, Yuya Ikeda, Maho Tsubota, Shigeru Yoshida, Huy Du Nguyen, Takuya Okada, Naoki Toyooka, Atsufumi Kawabata

TOXICOLOGY (2019)

Article Biochemistry & Molecular Biology

Dietary ascorbic acid restriction in GNL/SMP30-knockout mice unveils the role of ascorbic acid in regulation of somatic and visceral pain sensitivity

Maho Tsubota, Kenta Uebo, Koki Miki, Fumiko Sekiguchi, Akihiko Ishigami, Atsufumi Kawabata

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)

Article Pharmacology & Pharmacy

Genetic deletion of Cav3.2 T-type calcium channels abolishes H2S-dependent somatic and visceral pain signaling in C57BL/6 mice

Kazuki Matsui, Maho Tsubota, Saaya Fukushi, Nene Koike, Hiroshi Masuda, Yoshihito Kasanami, Takaya Miyazaki, Fumiko Sekiguchi, Tsuyako Ohkubo, Shigeru Yoshida, Yutaro Mukai, Akira Oita, Mitsutaka Takada, Atsufumi Kawabata

JOURNAL OF PHARMACOLOGICAL SCIENCES (2019)

Article Immunology

Role of non-macrophage cell-derived HMGB1 in oxaliplatin-induced peripheral neuropathy and its prevention by the thrombin/thrombomodulin system in rodents: negative impact of anticoagulants

Maho Tsubota, Ryotaro Fukuda, Yusuke Hayashi, Takaya Miyazaki, Shin Ueda, Rika Yamashita, Nene Koike, Fumiko Sekiguchi, Hidenori Wake, Shuji Wakatsuki, Yuka Ujiie, Toshiyuki Araki, Masahiro Nishibori, Atsufumi Kawabata

JOURNAL OF NEUROINFLAMMATION (2019)

Article Pharmacology & Pharmacy

Tacrolimus, a calcineurin inhibitor, promotes capsaicin-induced colonic pain in mice

Kazuki Matsui, Yuka Terada, Maho Tsubota, Fumiko Sekiguchi, Atsufumi Kawabata

JOURNAL OF PHARMACOLOGICAL SCIENCES (2020)

Article Pharmacology & Pharmacy

HMGB1 and its membrane receptors as therapeutic targets in an intravesical substance P-induced bladder pain syndrome mouse model

Yuhei Irie, Maho Tsubota, Mariko Maeda, Shiori Hiramoto, Fumiko Sekiguchi, Hiroyasu Ishikura, Hidenori Wake, Masahiro Nishibori, Atsufumi Kawabata

JOURNAL OF PHARMACOLOGICAL SCIENCES (2020)

Review Biochemistry & Molecular Biology

Role of HMGB1 in Chemotherapy-Induced Peripheral Neuropathy

Fumiko Sekiguchi, Atsufumi Kawabata

Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is resistant to most existing medicines and is one of the major dose-limiting side effects of chemotherapeutic agents. HMGB1 plays a key role in the development of CIPN, while TMα is effective in preventing CIPN in both animal models and patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Review Cell Biology

Macrophage as a Peripheral Pain Regulator

Risa Domoto, Fumiko Sekiguchi, Maho Tsubota, Atsufumi Kawabata

Summary: Neuroimmune crosstalk plays a crucial role in both somatic and visceral pathological pain, with macrophages interacting with neurons to regulate pain signals in peripheral tissues; recent studies have uncovered different characteristics and mediators of macrophages from various sources, highlighting their multitasking abilities in homeostatic conditions.

CELLS (2021)

Article Cell Biology

Caspase-Dependent HMGB1 Release from Macrophages Participates in Peripheral Neuropathy Caused by Bortezomib, a Proteasome-Inhibiting Chemotherapeutic Agent, in Mice

Maho Tsubota, Takaya Miyazaki, Yuya Ikeda, Yusuke Hayashi, Yui Aokiba, Shiori Tomita, Fumiko Sekiguchi, Dengli Wang, Masahiro Nishibori, Atsufumi Kawabata

Summary: Bortezomib-induced chemotherapy-induced peripheral neuropathy (CIPN) involves caspase-dependent release of HMGB1 from macrophages, leading to the activation of RAGE and CXCR4 receptors. Preventative measures for CIPN include the use of anti-HMGB1-neutralizing antibodies, thrombomodulin alfa, RAGE and CXCR4 antagonists, or macrophage depletion.

CELLS (2021)

Article Pharmacology & Pharmacy

Involvement of NF-κB in the upregulation of cystathionine-γ-lyase, a hydrogen sulfide-forming enzyme, and bladder pain accompanying cystitis in mice

Tomoka Ozaki, Maho Tsubota, Fumiko Sekiguchi, Atsufumi Kawabata

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2018)

No Data Available